FIGURE

Fig. 3

ID

ZDB-FIG-210119-13

Publication

El-Sahli et al., 2021 - A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature

Other Figures

All Figure Page

Back to All Figure Page

Fig. 3

Verteporfin in combination with combretastatin more effectively inhibits vasculature in transgenic zebrafish (Tg, fli:eGFP) embryos.

The zebrafish embryos at 8-hrs post fertilization were treated with drugs for 48 hrs. A Healthy zebrafish embryo taken at 8× magnification. Intersegmental vessel (ISV) phenotypes in a sectional view of: B DMSO; C CA4, 5 nM; D V, verteporfin, 250 nM; E V + CA4. F Graphical summary showing the ISV disruption ratio of B–E. Data are expressed as mean ± SEM, n = 5 embryos. G, H RT-qPCR analysis of vascular endothelial growth factor A (VEGFA, an angiogenesis gene) and VEGF receptor kdr in zebrafish embryos after treatments. Data are expressed as mean ± SEM, n = 4 embryos. *P < 0.05, **P < 0.01, ****P < 0.0001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Dis.